Urine test may reveal which prostate cancers are truly dangerous

NCT ID NCT03237702

Recruiting now Knowledge-focused Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to find new markers in urine that can tell the difference between aggressive prostate cancer and slow-growing types that don't need treatment. Researchers will analyze urine samples from 2000 men before and after they take a multi-carotenoid supplement for 8 weeks. The goal is to improve screening and reduce overtreatment of harmless prostate cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Multi-carotenoids (dietary supplement)
What this could lead to: If successful, this could lead to a simple urine test to better identify aggressive prostate cancers and avoid unnecessary treatment for harmless ones.
What could go wrong: This is an early-stage observational study, not a treatment trial. The urine markers may not prove accurate enough for clinical use, and the supplement part is small and short-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SIGNIFICANT PROSTATE CANCER

Contacts and locations

Locations

Department of Urology, National Taiwan University Hospital
RECRUITING

Taipei, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.